While monoclonal antibodies targeting IL-1α and IL-1β have transformed the management of autoinflammatory, rheumatologic, and cardiovascular disease, their efficacy is often limited by poor tissue penetration, compensatory cytokine networks, and systemic immunosuppression risks. This evidence concerns the gene IL1A and cardiovascular disorder.